Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of type 2 diabetes
3.2.1.2 Growing adoption of oral antidiabetic drugs
3.2.1.3 Growing awareness of diabetes management
3.2.2 Industry pitfalls & challenges
3.2.2.1 Adverse side effects
3.2.2.2 Competition from alternative therapies
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Acarbose
5.3 Miglitol
5.4 Voglibose
5.5 Combination drugs
Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Type 2 diabetes mellitus
6.3 Pre-diabetes
Chapter 7 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Branded
7.3 Generic
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 Saudi Arabia
9.6.2 South Africa
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Alkem Laboratories Ltd.
10.2 Bayer AG
10.3 Cipla Limited
10.4 Dr. Reddy's Laboratories Ltd.
10.5 Emcure Pharmaceuticals Ltd.
10.6 Lupin Ltd.
10.7 Merck & Co.
10.8 Novartis AG
10.9 Sanofi SA
10.10 Sun Pharmaceutical Industries Ltd.
10.11 Takeda Pharmaceutical Company
10.12 Torrent Pharmaceuticals Ltd.
10.13 Unichem Laboratories Ltd.
